PORTOLA VALLEY, Calif., June 18, 2012 /PRNewswire/ -- Spectros Corporation announces the successful launch of OnCall wireless remote access for viewing real-time patient results on T-Stat white light tissue oximeters.
OnCall changes the standard of healthcare by improving patient monitoring and decreasing the delayed response time to critical care events. Surgeons have long awaited an easy and simple approach to remote monitoring that is not limited to a specific phone application, but available with any wireless connection that may be available. The program was developed by Spectros Corporation and is compliant with all HIPAA requirements to insure safety and efficacy. "Human error and lack of communication between health care providers is a variable that cannot always be controlled. Removing this factor reduces failure rates and provides more confidence in both patients and surgeons." Elizabeth van Thillo Rohlff, Director of Marketing and Sales.
The OnCall remote monitoring feature is easily added to any existing T-Stat VLS tissue oximeter or built into any of the other broadband optical patient monitors being developed by leading optical engineers at Spectros Corp. The reconstructive plastic surgery market is the first to adopt the OnCall system and will be followed by the gastroenterology and critical care fields currently using T-Stat.
"This, coupled with our broadband technology, puts us well beyond our competitors,*" said van Thillo Rohlff. "Soon all patient monitors will be moving towards this model as the standard of care continues to advance and adopt new and progressive technologies. Remote patient monitoring is the future of patient monitoring and Spectros is proud to be part of it. Today's common smart phone is tomorrow's patient monitoring access point and we are proud to be helping healthcare teams by developing an easy to use and reliable system."
Spectros markets advanced molecular devices that shed light on ischemia and cancer. Spectros is also developing molecular imaging contrast agents for surgical guidance during breast and prostate cancer surgeries, currently undergoing phase I/II clinical trials. Spectros is a venture-supported concern.
(Note: Forward-looking statements do not constitute an offer for investment nor a guarantee of future events or returns. Certain applications described above have not been reviewed by the FDA, and are therefore labeled for investigational use only. T-Stat is a trademark of Spectros.)
*INVOS is a trademark of Somanetics and Covidien. FORE-SIGHT is a trademark of CAS Medical. T.Ox is trademark of ViOptix.
For further information, visit www.spectros.com.
Web Site: http://www.spectros.com
CONTACT: Elizabeth van Thillo Rohlff, firstname.lastname@example.org.
SOURCE Spectros Corporation